Page 1 | Search Results | Diabetes | American Diabetes Association

1-20 of 145

Sort by

Sort Order Select

Journal Articles

Overexpressed Poldip2 Incurs Retinal Fibrosis via the TGF-β1/SMAD3 Signaling Pathway in Diabetic Retinopathy

Zhiyu Ji, Siyu Lin, Siyu Gui, Jie Gao, Fan Cao, Yiming Guan, Qinyu Ni, Keyang Chen, Liming Tao, Jiang Zhengxuan

Diabetes 2024;73(10):1742–1755

https://doi.org/10.2337/db23-1036

Published: 05 July 2024

View article titled, Overexpressed Poldip2 Incurs Retinal Fibrosis via the TGF-β1/SMAD3 Signaling Pathway in Diabetic Retinopathy

Journal Articles

Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation

Xue Han, Jiajia Wei, Ruyi Zheng, Yu Tu, Mengyang Wang, Lingfeng Chen, Zheng Xu, Lei Zheng, Chao Zheng, Qiaojuan Shi, Huazhong Ying, Guang Liang

Diabetes 2024;73(5):780–796

https://doi.org/10.2337/db23-0700

Published: 23 February 2024

View article titled, Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation

Journal Articles

Exocrine Pancreas in Type 1 and Type 2 Diabetes: Different Patterns of Fibrosis, Metaplasia, Angiopathy, and Adiposity

Jordan J. Wright, Adel Eskaros, Annika Windon, Rita Bottino, Regina Jenkins, Amber M. Bradley, Radhika Aramandla, Sharon Philips, Hakmook Kang, Diane C. Saunders, Marcela Brissova, Alvin C. Powers

Diabetes 2024;73(7):1140–1152

https://doi.org/10.2337/db23-0009

Published: 26 October 2023

View article titled, Exocrine Pancreas in Type 1 and Type 2 Diabetes: Different Patterns of Fibrosis, Metaplasia, Angiopathy, and Adiposity

Journal Articles

IL-6 Trans-Signaling Is Increased in Diabetes, Impacted by Glucolipotoxicity, and Associated With Liver Stiffness and Fibrosis in Fatty Liver Disease

Aysim Gunes, Clémence Schmitt, Laurent Bilodeau, Catherine Huet, Assia Belblidia, Cindy Baldwin, Jeanne-Marie Giard, Laurent Biertho, Annie Lafortune, Christian Yves Couture, Angela Cheung, Bich N. Nguyen, Eithan Galun, Chantal Bémeur, Marc Bilodeau, Mathieu Laplante, An Tang, May Faraj, Jennifer L. Estall

Diabetes 2023;72(12):1820–1834

https://doi.org/10.2337/db23-0171

Published: 27 September 2023

View article titled, IL-6 Trans-Signaling Is Increased in Diabetes, Impacted by Glucolipotoxicity, and Associated With Liver Stiffness and Fibrosis in Fatty Liver Disease

Journal Articles

Obesity Enables NLRP3 Activation and Induces Myocardial Fibrosis via Hyperacetylation of HADHa

Yan Deng, Xin Liu, Min Xie, Rui Zhao, Liwei Ji, Kuo Tang, Wei Yang, Wei Ou, Maodi Xie, Tao Li

Diabetes 2023;72(11):1597–1608

https://doi.org/10.2337/db23-0264

Published: 25 August 2023

View article titled, Obesity Enables NLRP3 Activation and Induces Myocardial Fibrosis via Hyperacetylation of HADHa

Journal Articles

Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes

Saori Sako, Yumie Takeshita, Hiroaki Takayama, Hisanori Goto, Yujiro Nakano, Hitoshi Ando, Hiromasa Tsujiguchi, Tatsuya Yamashita, Kuniaki Arai, Shuichi Kaneko, Hiroyuki Nakamura, Kenichi Harada, Masao Honda, Toshinari Takamura

Diabetes 2023;72(9):1297–1306

https://doi.org/10.2337/db22-0933

Published: 21 June 2023

View article titled, Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes

Meeting Abstracts

407-P: Efficacy of Finerenone in Patients with Abnormal Markers of Liver Steatosis and Fibrosis—A FIDELITY Subgroup Analysis

NIKOLAOS PERAKAKIS, STEFAN R. BORNSTEIN, ANDREAS L. BIRKENFELD, ANDREAS LINKERMANN, STEFAN ANKER, GERASIMOS FILIPPATOS, BERTRAM PITT, PETER ROSSING, LUIS M. RUILOPE, PETER KOLKHOF, ROBERT LAWATSCHECK, CHARLIE SCOTT, GEORGE BAKRIS

Diabetes 2023;72(Supplement_1):407-P

https://doi.org/10.2337/db23-407-P

Published: 20 June 2023

View article titled, 407-P: Efficacy of Finerenone in Patients with Abnormal Markers of Liver Steatosis and Fibrosis—A FIDELITY Subgroup Analysis

Meeting Abstracts

1351-P: Caffeine Intake Is Associated with a Lower Risk of Nonalcoholic Fatty Liver Disease–Related Fibrosis in Patients with Type 2 Diabetes

JIAHAO HAN, CHUAN LIU, HUANHUAN YANG, RUIXIA GAO, ZHIHUI LI, JIA LI, XIAOLONG QI

Diabetes 2023;72(Supplement_1):1351-P

https://doi.org/10.2337/db23-1351-P

Published: 20 June 2023

View article titled, 1351-P: Caffeine Intake Is Associated with a Lower Risk of Nonalcoholic Fatty Liver Disease–Related Fibrosis in Patients with Type 2 Diabetes

Meeting Abstracts

425-P: Renin-Angiotensin System Inhibition in Combination with Glucagon-Like Peptide 1 Receptor Agonist Treatment Improve Levels of a Kidney Fibrosis Biomarker in Persons with Type 2 Diabetes

ALEXANDRA MØLLER, STEFANIE THÖNI, CLARA F.G. LAURSEN, MORTEN A. KARSDAL, FEDERICA GENOVESE, DANIEL GULDAGER KRING RASMUSSEN

Diabetes 2023;72(Supplement_1):425-P

https://doi.org/10.2337/db23-425-P

Published: 20 June 2023

View article titled, 425-P: Renin-Angiotensin System Inhibition in Combination with Glucagon-Like Peptide 1 Receptor Agonist Treatment Improve Levels of a Kidney Fibrosis Biomarker in Persons with Type 2 Diabetes

Meeting Abstracts

1396-P: Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis among Subjects without Type 2 Diabetes (T2D)

PEGAH GOLABI, JAMES M. PAIK, AMEETA KUMAR, NAGASHREE GUNDURAO, KENNETH CUSI, ZOBAIR YOUNOSSI

Diabetes 2023;72(Supplement_1):1396-P

https://doi.org/10.2337/db23-1396-P

Published: 20 June 2023

View article titled, 1396-P: Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis among Subjects without Type 2 Diabetes (T2D)

Meeting Abstracts

1339-P: Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)

ENRIQUE VALDEZ SAENZ, EDDISON GODINEZ LEIVA, ROMINA LOMONACO, SRILAXMI KALAVALAPALLI, STEPHEN A. MARANGI, MARIA A. GONZALEZ, ANDREA ORTIZ ROCHA, XIAOFEI CHI, MATTHEW J. GURKA, DIANA BARB, ANU SHARMA, KENNETH CUSI

Diabetes 2023;72(Supplement_1):1339-P

https://doi.org/10.2337/db23-1339-P

Published: 20 June 2023

View article titled, 1339-P: Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)

Meeting Abstracts

1260-P: Verifying the Use of FIB4 and BARD Scores to Predict Advanced Fibrosis Using Transient Elastography in People with Type 2 Diabetes in a Tertiary Care Center in India

AJOY TEWARI, JAY TEWARI, ANUJ MAHESHWARI, VINEETA TEWARI, BHAGWAT TEWARI

Diabetes 2023;72(Supplement_1):1260-P

https://doi.org/10.2337/db23-1260-P

Published: 20 June 2023

View article titled, 1260-P: Verifying the Use of FIB4 and BARD Scores to Predict Advanced Fibrosis Using Transient Elastography in People with Type 2 Diabetes in a Tertiary Care Center in India

Meeting Abstracts

1349-P: People with Type 2 Diabetes Have a High Prevalence of Nonalcoholic Steatohepatitis with Significant Fibrosis When Screened by NIS4 or Elastography

SRILAXMI KALAVALAPALLI, EDDISON GODINEZ LEIVA, ROMINA LOMONACO, STEPHEN A. MARANGI, ENRIQUE VALDEZ SAENZ, ANDREA ORTIZ ROCHA, JEFFREY T. BUDD, YASMINE MOHSENI, KELLY Y. CHUN, TONI R. PREZANT, MARGERY A. CONNELLY, DIANA BARB, KENNETH CUSI

Diabetes 2023;72(Supplement_1):1349-P

https://doi.org/10.2337/db23-1349-P

Published: 20 June 2023

View article titled, 1349-P: People with Type 2 Diabetes Have a High Prevalence of Nonalcoholic Steatohepatitis with Significant Fibrosis When Screened by NIS4 or Elastography

Meeting Abstracts

1347-P: Utility of Fibrosis-4 (FIB-4) and Nonalcoholic Fatty Liver Disease Fibrosis Scores (NFS) for Liver Fibrosis Screening in Asian-Indians with Type 2 Diabetes—A Cross-Sectional Observational Study

K. V RAVI TEJA, SHIVANI CHANDEL

Diabetes 2023;72(Supplement_1):1347-P

https://doi.org/10.2337/db23-1347-P

Published: 20 June 2023

View article titled, 1347-P: Utility of Fibrosis-4 (FIB-4) and Nonalcoholic Fatty Liver Disease Fibrosis Scores (NFS) for Liver Fibrosis Screening in Asian-Indians with Type 2 Diabetes—A Cross-Sectional Observational Study

Meeting Abstracts

255-LB: Liver Pyruvate Carboxylase Deletion in Mice Prevents Fibrosis from a NASH Diet

MELISSA MAE R. IÑIGO-VOLLMER, BLANKA KUCEJOVA, MONIKA N. MIZERSKA, SHAHANSHAH KHAN, PAMELA A. SZWEDA, HASAN ZAKI, LUKE I. SZWEDA, XIAORONG FU, SHAWN C. BURGESS

Diabetes 2023;72(Supplement_1):255-LB

https://doi.org/10.2337/db23-255-LB

Published: 20 June 2023

View article titled, 255-LB: Liver Pyruvate Carboxylase Deletion in Mice Prevents Fibrosis from a NASH Diet

Meeting Abstracts

1342-P: Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?

ANDREA ORTIZ ROCHA, EDDISON GODINEZ LEIVA, SRILAXMI KALAVALAPALLI, ROMINA LOMONACO, SHWETHA S. SHETTY, STEPHEN A. MARANGI, ENRIQUE VALDEZ SAENZ, SULAV SHRESTHA, MARIA A. GONZALEZ, XIAOFEI CHI, MATTHEW J. GURKA, DIANA BARB, KENNETH CUSI

Diabetes 2023;72(Supplement_1):1342-P

https://doi.org/10.2337/db23-1342-P

Published: 20 June 2023

View article titled, 1342-P: Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?

Journal Articles

Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering

Rui Xu, Jing Fu, Yuting Hu, Xiaoyan Yang, Xiang Tao, Long Chen, Kai Huang, Qin Fu

Diabetes 2022;71(8):1660–1678

https://doi.org/10.2337/db21-0898

Published: 21 August 2022

View article titled, Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering

Journal Articles

The Mechanism for Adipose Endotrophin Production

Yun Sok Lee

Diabetes 2022;71(8):1617–1619

https://doi.org/10.2337/dbi22-0008

Published: 21 August 2022

View article titled, The Mechanism for Adipose Endotrophin Production

Journal Articles

PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo

Edwige Schreyer, Cathy Obringer, Nadia Messaddeq, Bruno Kieffer, Paul Zimmet, Alexander Fleming, Tarekegn Geberhiwot, Vincent Marion

Diabetes 2022;71(9):2034–2047

https://doi.org/10.2337/db22-0058

Published: 13 July 2022

View article titled, PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo

Meeting Abstracts

1121-P: The Combination of the ELF and FIB-4 Scores Have High Predictive Performance for Significant or Advanced Fibrosis in Patients with NAFLD

ZOBAIR YOUNOSSI, SEAN FELIX, THOMAS JEFFERS, ELENA YOUNOSSI, FATEMA NADER, ANDREI RACILA, BRIAN P. LAM, MARIA STEPANOVA

Diabetes 2022;71(Supplement_1):1121-P

https://doi.org/10.2337/db22-1121-P

Published: 01 June 2022

View article titled, 1121-P: The Combination of the ELF and FIB-4 Scores Have High Predictive Performance for Significant or Advanced Fibrosis in Patients with NAFLD

NARROW

Overexpressed Poldip2 Incurs Retinal Fibrosis via the TGF-β1/SMAD3 Signaling Pathway in Diabetic Retinopathy

Macrophage SHP2 Deficiency Alleviates Diabetic Nephropathy via Suppression of MAPK/NF-κB– Dependent Inflammation

Exocrine Pancreas in Type 1 and Type 2 Diabetes: Different Patterns of Fibrosis, Metaplasia, Angiopathy, and Adiposity

IL-6 Trans-Signaling Is Increased in Diabetes, Impacted by Glucolipotoxicity, and Associated With Liver Stiffness and Fibrosis in Fatty Liver Disease

Obesity Enables NLRP3 Activation and Induces Myocardial Fibrosis via Hyperacetylation of HADHa

Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes

407-P: Efficacy of Finerenone in Patients with Abnormal Markers of Liver Steatosis and Fibrosis—A FIDELITY Subgroup Analysis

1351-P: Caffeine Intake Is Associated with a Lower Risk of Nonalcoholic Fatty Liver Disease–Related Fibrosis in Patients with Type 2 Diabetes

425-P: Renin-Angiotensin System Inhibition in Combination with Glucagon-Like Peptide 1 Receptor Agonist Treatment Improve Levels of a Kidney Fibrosis Biomarker in Persons with Type 2 Diabetes

1396-P: Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) and Advanced Fibrosis among Subjects without Type 2 Diabetes (T2D)

1339-P: Hepatic Steatosis and Fibrosis Are Common in Obese Patients with Type 2 Diabetes Mellitus (T2DM)

1260-P: Verifying the Use of FIB4 and BARD Scores to Predict Advanced Fibrosis Using Transient Elastography in People with Type 2 Diabetes in a Tertiary Care Center in India

1349-P: People with Type 2 Diabetes Have a High Prevalence of Nonalcoholic Steatohepatitis with Significant Fibrosis When Screened by NIS4 or Elastography

1347-P: Utility of Fibrosis-4 (FIB-4) and Nonalcoholic Fatty Liver Disease Fibrosis Scores (NFS) for Liver Fibrosis Screening in Asian-Indians with Type 2 Diabetes—A Cross-Sectional Observational Study

255-LB: Liver Pyruvate Carboxylase Deletion in Mice Prevents Fibrosis from a NASH Diet

1342-P: Are Plasma Aminotransferases of Value in Screening Patients with T2DM for NAFLD or Fibrosis?

Roflumilast-Mediated Phosphodiesterase 4D Inhibition Reverses Diabetes-Associated Cardiac Dysfunction and Remodeling: Effects Beyond Glucose Lowering

The Mechanism for Adipose Endotrophin Production

PATAS, a First-in-Class Therapeutic Peptide Biologic, Improves Whole-Body Insulin Resistance and Associated Comorbidities In Vivo

1121-P: The Combination of the ELF and FIB-4 Scores Have High Predictive Performance for Significant or Advanced Fibrosis in Patients with NAFLD

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

Email alerts

Journals

Books

Clinical Compendia

News

Podcasts

Other

About

Resources

This Feature Is Available To Subscribers Only